Quince Stock Price, News & Analysis

Quince Therapeutics (Nasdaq: QNCX) reported a positive pre-planned safety review by an independent data and safety monitoring board (iDSMB) for its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T).

The iDSMB found no safety concerns and recommended the study continue without modifications. The international, multicenter, randomized, double-blind, placebo-controlled trial enrolls two cohorts (1:1 randomization) with six infusions given every 21–30 days. The primary endpoint is change from baseline to last efficacy visit on the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS). Quince expects to report topline results in Q1 2026.

Quince Therapeutics (Nasdaq: QNCX) presented a poster on patient‑reported walking capacity in children with Ataxia‑Telangiectasia (A‑T) at the 54th Child Neurology Society Annual Meeting on October 9, 2025.

The cross‑sectional natural history analysis used data from 372 children in the Global A‑T Family Data Platform to describe age‑related loss of ambulation. A patient‑reported walking scale was compared with clinician measures ICARS and RmICARS, showing all three scales tracked walking decline similarly. Findings suggest the RmICARS walking components may be suitable for assessing A‑T disease progression and are relevant to the company's Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP, NCT06193200).

Quince Therapeutics (Nasdaq: QNCX) announced the publication of a population pharmacokinetic modeling study for its Phase 3 lead asset, eDSP, in the journal CPT: Pharmacometrics & Systems Pharmacology. The study focused on pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults.

The research demonstrated that eDSP, which encapsulates dexamethasone sodium phosphate in patients' own red blood cells, maintains sustained plasma concentrations for 20-30 days without drug accumulation. The PK model, developed using data from 24 healthy adults and 109 pediatric A-T patients, confirmed eDSP's sustained release properties and favorable safety profile with minimal corticosteroid-related side effects.

Quince Therapeutics (Nasdaq: QNCX) announced it will host a virtual Investor Day on October 2, 2025, from 10:00 AM to 12:00 PM ET. The event will showcase the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and proprietary eDSP System for chronic corticosteroid delivery.

Key presentations will cover their pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), with topline results expected in Q1 2026. The company will discuss its regulatory pathway, including Special Protocol Assessment agreement with FDA, orphan drug and Fast Track designations. Additional topics include commercial launch preparations with Option Care Health and potential expansion into other rare diseases like Duchenne muscular dystrophy.

Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focused on rare disease treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation that will be available on September 5, 2025, at 7:00 a.m. ET.

Investors can access the presentation webcast through Quince's Investor Relations website at ir.quincetx.com, with an archive available after the event.

Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.

Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.

Quince Therapeutics (Nasdaq: QNCX) has established a strategic partnership with Option Care Health (Nasdaq: OPCH) for the commercial development and launch of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the United States.

Option Care Health will provide nationwide specialty pharmacy and infusion services through its network of 90+ pharmacies and 180+ ambulatory infusion suites. The partnership aims to enhance access to eDSP treatment for patients with Ataxia-Telangiectasia (A-T), with potential expansion to treat Duchenne muscular dystrophy (DMD).

The collaboration includes comprehensive services such as logistics management, patient registration, hub support, clinician-delivered services, and data reporting to support eDSP's commercial launch, pending positive study results and regulatory approval.

Quince Therapeutics (Nasdaq: QNCX) has completed enrollment in its pivotal Phase 3 NEAT clinical trial evaluating eDSP for treating Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease. The trial has enrolled 105 total participants, including 83 in the primary analysis population (ages 6-9) and 22 participants aged 10 or older.

The study, conducted under a Special Protocol Assessment agreement with the FDA, features a 90% statistical power for the primary endpoint. Quince expects to report topline results in Q1 2026 and plans to submit a New Drug Application to the FDA in H2 2026. The company's eDSP System has received FDA Fast Track designation, highlighting its potential to address high unmet medical needs in A-T treatment.

Quince Therapeutics (Nasdaq: QNCX) has appointed Dr. Hassan Abolhassani to its Scientific Advisory Board (SAB) as its ninth member. Dr. Abolhassani, an Assistant Professor at the Karolinska Institutet, is a leading immunologist recognized in the top 1% of highly cited researchers in immunology.

The appointment strengthens Quince's SAB as the company advances its lead asset eDSP, currently in a Phase 3 clinical trial for Ataxia-Telangiectasia (A-T). The company expects to report topline results in Q1 2026. Beyond A-T and Duchenne muscular dystrophy, Quince is exploring 11 additional rare disease indications for eDSP where corticosteroid treatment could be beneficial without associated toxicities.